In a large African trial described at CROI 2009, rates of both virologic failure and drug discontinuation were lower with lopinavir/r-based regimens than with nevirapine-based ones.
In October 2008, the National Institute of Allergy and Infectious Diseases reported preliminary results from the OCTANE trial, showing that lopinavir/ritonavir-based regimens are more effective than nevirapine-based ones in women with previous exposure to single-dose nevirapine (JW AIDS Clin Care Nov 17 2008. At this year’s Retrovirus Conference, Shahin Lockman described those results in greater detail [Abstract 94LB].
The OCTANE study is an ongoing, randomized, phase III trial being conducted in seven African countries to evaluate whether a boosted PI is superior to nevirapine in first-line regimens also containing tenofovir/FTC. The primary endpoint is time to death or virologic failure, with the latter defined as a <1-log copies/mL decrea…